Skip to main content

What the FDA labels say about taking them together

Gemfibrozil and glyburide

Gemfibrozil's FDA label of April 10, 2026 names glyburide in its drug interactions section; the glyburide label PlainMeds reads does not name gemfibrozil. The gemfibrozil label: “(D) OATP1B1 substrates: Gemfibrozil is an inhibitor of OATP1B1 transporter and may increase exposure of drugs that are substrates of OATP1B1.”

Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the glyburide FDA label on DailyMed (effective July 1, 2021, TEVA Pharmaceuticals USA Inc).

What does the gemfibrozil label say about glyburide?

Gemfibrozil label, drug interactions

(D) OATP1B1 substrates: Gemfibrozil is an inhibitor of OATP1B1 transporter and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan).

Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed

What does the glyburide label say about gemfibrozil?

Glyburide's label (effective July 1, 2021) does not name gemfibrozil in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Glyburide), NDA017532 (Sanofi Aventis Us), as published by TEVA Pharmaceuticals USA Inc, effective July 1, 2021 (SPL set 50d16f1d-c814-4411-8749-62561321ecce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

27Gemfibrozil generic labelers
16Glyburide generic labelers
GemfibrozilGlyburide
Labeled forHigh cholesterol, Heart attack and coronary artery diseaseType 2 diabetes
Boxed warningYesNo
Pharmacy cost (NADAC)$0.104 per tablet 600 mg tablet$0.0643 per tablet 5 mg tablet
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?